Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
July 30, 2021

USFDA authorises baricitinib for emergency use as monotherapy for Covid-19 patients

The US Food and Drug Administration (FDA) has extended the Emergency Use Authorization (EUA) for Eli Lilly and Company and Incyte's baricitinib to treat Covid-19 patients with or without remdesivir.

Eli Lilly corporate centre in Indianapolis, Indiana. Credit: Momoneymoproblemz/ wikimedia.